Lobby organisation
AbbVie
Company · Health & pharma · HQ: United States · Transparency Register entry
As of 7 November 2026, AbbVie appears in 70 declared MEP meetings (41 different MEPs), most often with European People's Party.
In their own words
“AbbVie is a Specialty-focused, research-based biopharmaceutical company focused on developing new products and new ways to help people manage some of the most serious health conditions. We are scientists, researchers, communicators, manufacturing specialists, and regulatory experts. AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott.”
Read the rest of the statementShow less of the statement
“Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries. On January 1, 2013, AbbVie was founded, a global biopharmaceutical company with the focus and capabilities to address some of the world's greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop, and bring to market groundbreaking science to solve the biggest health problems that face the world today (...)”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 70 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2022–2026. Bar length is relative to its busiest year (27 in 2025). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 21 Oct 2026 | Nina Carberry | Neurological health |
| 20 Oct 2026 | Tiemo Wölken | MDR/IVDR Revision and Biotech Act |
| 15 Oct 2026 | Elena Nevado del Campo | Neurological health strategy |
| 29 Jun 2026 | Eleonora Meleti | WOMEN'S HEALTH |
| 25 Jun 2026 | Ingeborg ter Laak | Biotech Act |
| 4 Jun 2026 | Aurelijus Veryga | Strengthening Europe's Biotech Ecosystem |
| 1 Jun 2026 | Maria Grapini | Meeting on Pharmaceutical products |
| 1 Jun 2026 | Maria Grapini | healthcare |
| 1 Jun 2026 | Gabriela Firea | Meeting on EU health policy |
| 1 Jun 2026 | Gabriela Firea | Health at a Crossroads: Active Aging, Prevention & Demographic Resilience |
| 7 May 2026 | Wouter Beke | EU Biotech Act I |
| 28 Apr 2026 | Ingeborg ter Laak | Biotech Act |
| 9 Apr 2026 | Aurelijus Veryga | Follow-Up Discussion on the Critical Medicines Act |
| 9 Apr 2026 | Margarita de la Pisa Carrión | SANT COMMITTEE ONGOING WORK |
| 25 Mar 2026 | Tomislav Sokol | Health policy |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.